CTOs on the Move

4C Medical Technologies

www.4cmed.com

 
4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR).
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.4cmed.com
  • 7600 Boone Avenue Suite 7
    Brooklyn Park, MN USA 55428
  • Phone: 612.600.8951

Executives

Name Title Contact Details

Funding

4C Medical Technologies raised $17M on 09/10/2018
4C Medical Technologies raised $10M on 12/28/2020

Similar Companies

Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children.

Dalton Pharma Services

Dalton Pharma Services is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triumvira

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, with our research facilities in Hamilton, Ontario.

Applied Biosystems by Life Technologies

AXYS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, design and development of therapeutic small molecules that address significant markets with major unmet medical needs. AXYS collaborates with large pharmaceutical

Horizon Discovery

Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted...